Vaxxinity announces first subjects dosed in phase 1 clinical trial of vxx-401, investigational anti-pcsk9 vaccine to treat hypercholesterolemia

Cape canaveral, fla., march 20, 2023 (globe newswire) -- vaxxinity, inc. (nasdaq: vaxx), a u.s. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first subjects have been dosed in a randomized, double-blind, placebo-controlled phase 1 clinical trial of vxx-401, an investigational vaccine designed to lower low-density lipoprotein (ldl) cholesterol, a known factor contributing to heart disease, by targeting proprotein convertase subtilisin/kexin type 9 serine protease (pcsk9). heart disease remains the leading cause of death globally, claiming over 18 million lives per year, despite the existence of approved treatments that lower ldl.
VAXX Ratings Summary
VAXX Quant Ranking